Work

A Novel Competing-Risk Model Integrating Systemic Inflammation to Predict Acute-on-Chronic Liver Failure

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Aims: Absolute risk of acute-on-chronic liver failure (ACLF) can be overestimated when the hazards of competing events, such as liver transplantation (LT) or death without ACLF, are not incorporated. We developed and validated a novel competing-risk-based model integrating systemic inflammation to predict ACLF development. Methods: The derivation cohort comprised 1,146 patients with acute decompensation of cirrhosis from the prospective, multicenter Korean Acute-on-Chronic Liver Failure (KACLiF) cohort. External validation used a retrospective 1,104-patient cohort. The study followed the TRIPOD+AI reporting guidelines and applied a Fine-Gray subdistribution hazard model accounting for the competing risks of death or LT, with predictive performance evaluated using the C-index and time-dependent area under the receiver operating characteristic curve (AUROC). Results: The KACLiF-ACLF score integrated C-reactive protein, albumin, total bilirubin, international normalized ratio, and creatinine. In derivation, the competing-risk C-index (0.806 at 28 days; 0.791 at 90 days) significantly exceeded all eight comparators at 90 days, but not MELD or MELD-Na at 28 days. In external validation, it (0.892 and 0.889) significantly exceeded all comparators at both horizons. Time-dependent AUROCs at 28 days were 0.815 and 0.894, significantly exceeding all comparators at both horizons except MELD-Na at 28 days in derivation. Transported absolute risks were overpredicted, requiring recalibration. The model stratified patients into low-, intermediate-, and high-risk groups, correlating with cumulative ACLF incidence and transplant-free survival (P<0.001). Conclusions: The KACLiF-ACLF score discriminates ACLF development with high accuracy in external validation and supports risk stratification within a competing-risk framework. Recalibrated absolute risks require independent validation before clinical implementation.
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $32
OpenAlex ID: W7234732067
FWCI:
Cites: 29
Cited by:
Related to: 10